Kymera Therapeutics KYMR Operating Lease Liabilities (Total)
Operating Lease Liabilities (Total) at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's operating lease liabilities (total).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's operating lease liabilities (total)?
- Kymera Therapeutics (KYMR) reported operating lease liabilities (total) of $77.62M in Q1 2026.
- How has Kymera Therapeutics's operating lease liabilities (total) changed year-over-year?
- Kymera Therapeutics's operating lease liabilities (total) decreased by 6.3% year-over-year, from $82.86M to $77.62M.
- What is the long-term trend for Kymera Therapeutics's operating lease liabilities (total)?
- Over 5 years (2020 to 2025), Kymera Therapeutics's operating lease liabilities (total) has grown at a 36.4% compound annual growth rate (CAGR), from $16.7M to $78.98M.
- What does operating lease liabilities (total) mean?
- This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.